Technology Overview
ViRexx has three technology platforms, both of which harness the body's power to cure.
AIT™ Platform Technology
Antibody-based ImmunoTherapy (AIT™) enhances the human immune system’s ability to produce a highly specific and effective anti-tumour response.
Details on AIT™ technology platform
T-ACT™ Platform Technology
The T-ACT™ "Targeted-Autothrombogenic Cancer Therapy" platform is designed to cut off the blood supply to tumors, leading to tumor tissue starvation and death. The lead product of the T-ACT™ program is Occlusin™ Injection, which is being developed to treat uterine fibroids and tumors in the liver.
Details on T-ACT™ Platform Technology
Chimigen™ Platform Technology
The Chimigen™ platform educates the immune system to recognize and remove specific viruses in the body. HepaVaxx B and HepaVaxx C are being developed from the Chimigen™ platform to treat patients chronically infected with Hepatitis B and C.
Details on Chimigen™ Platform Technology